PMV Pharmaceuticals, Inc. — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing, not a standalone fourth-quarter report. PMV is a clinical-stage precision oncology company with no approved products and no product revenue.
Financial and operating highlights
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $52.0 million | $36.5 million |
| General and administrative expense | $25.1 million | $21.8 million |
| Total operating expenses | $77.0 million | $58.3 million |
| Net loss | $73.3 million | $57.8 million |
| Net loss per share | $1.61 | $1.28 |
| Cash used in operating activities | $63.8 million | $46.6 million |
| Cash, cash equivalents and marketable securities | $243.5 million | $314.1 million |
| Working capital | $236.2 million | $289.1 million |
- Operating loss was $77.0 million; net interest income of $3.6 million partly offset the loss. Profitability and operating margins are not meaningful because the company had no revenue.
- Cash and cash equivalents were $108.3 million, including $0.8 million restricted cash; current and noncurrent marketable securities were $135.3 million in total.
- Total liabilities were $24.3 million, principally operating lease liabilities of $14.0 million. The filing reports no funded debt.
- Investing activities used $1.4 million net, including $8.0 million of property and equipment purchases, largely offset by securities maturities. Financing activities provided $1.0 million, primarily from employee stock plans and option exercises.
- Accumulated deficit reached $241.0 million. The company reported $10.2 million of stock-based compensation expense in 2022.
Material changes versus FY 2021
- Net loss increased by $15.5 million, while operating expenses rose $18.7 million. R&D expense increased $15.5 million, mainly as PC14586 advanced through its Phase 1/2 trial; G&A increased $3.3 million, including higher staffing and headquarters-related costs.
- Operating cash use increased $17.2 million. Total cash, cash equivalents and marketable securities declined $70.5 million to $243.5 million.
- Net interest income rose $3.2 million to $3.6 million, reflecting higher interest rates, partly offset by lower average investment balances.
- Property and equipment purchases increased to $8.0 million from $1.3 million, associated with the Princeton headquarters and laboratory buildout.
Development, outlook and key risks
- Lead program: PC14586 is an oral candidate designed to restore wild-type function in tumors with the p53 Y220C mutation. In the Phase 1/2 trial, preliminary data through May 10, 2022 showed partial responses in 32% of 25 patients treated in the reported efficacious dose range, including six confirmed and two unconfirmed responses, across six tumor types. These are interim results and may change; the study is early-stage and open-label.
- PC14586 was generally well-tolerated in the reported monotherapy dataset of 41 patients; the maximum tolerated dose was 1,500 mg twice daily. Frequently reported adverse events included nausea, vomiting, AST/ALT increases, anemia, increased blood creatine and fatigue.
- In December 2022, enrollment opened in a combination arm evaluating PC14586 with Merck’s KEYTRUDA; approximately 36 patients were expected. Merck supplies KEYTRUDA, while PMV sponsors the trial.
- The R282W program was progressing toward lead optimization; other programs remained in discovery or preclinical development. PMV stated it expects research and development spending to rise as development advances.
- Management estimated available cash and investments would fund planned operations at least through 2024, based on assumptions that could prove incorrect. The financial-statement note separately states liquidity is adequate for at least 12 months from issuance. Additional capital may be needed, and could dilute shareholders or require unfavorable partnering or financing terms.
- Material risks include clinical and regulatory failure or delay, uncertain acceptance of the tumor-agnostic strategy, limited numbers of mutation-defined patients, dependence on PC14586, companion-diagnostic requirements, reliance on third-party clinical and manufacturing providers, and competition. The company also flags potential supply-chain exposure, including third-party activity in China, and macroeconomic, inflation, interest-rate and geopolitical risks.
- The company had no material legal proceedings reported as of February 28, 2023. The auditor issued an unqualified opinion on the financial statements; management concluded disclosure controls and internal control over financial reporting were effective as of year-end. The auditor did not express an opinion on internal-control effectiveness.
Important facts for investors to verify
- Subsequent PC14586 trial updates: response durability, confirmation of preliminary responses, safety, dose selection and enrollment progress, including the KEYTRUDA combination arm.
- Whether the cash runway remains consistent with management’s estimate through 2024, given the $63.8 million 2022 operating cash use and expected higher spending.
- Any financing, collaboration or licensing activity, and its potential effects on dilution, development rights and cash requirements.
- Progress of the R282W and other pipeline programs, and whether patient identification and companion-diagnostic plans can support development.
- Clinical supply, manufacturing, regulatory and intellectual-property developments that could delay trials or commercialization.